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Original research
Effectiveness of Subcutaneously 
Administered Leuprolide Acetate 
to Achieve Low Nadir Testosterone 
in Prostate Cancer Patients
Christopher M. Pieczonka, MD,1 Przemyslaw Twardowski, MD,2 Joseph Renzulli II, MD,3 
Jason Hafron, MD,4 Deborah M. Boldt-Houle, PhD,5 Stuart Atkinson, MB ChB,5 Scott Eggener, MD6 
1Associated Medical Professionals, Syracuse, NY; 2Providence Hospital Santa Monica, Santa Monica, CA; 
3Brown University, Providence, RI; 4Michigan Institute of Urology, Troy, MI; 5Tolmar Pharmaceuticals Inc., 
Lincolnshire, IL; 6University of Chicago, Chicago, IL
Evidence suggests lower nadir testosterone levels during the first year of androgen 
deprivation therapy improve advanced prostate cancer clinical outcomes. We evaluated 
pivotal trials for subcutaneously administered leuprolide acetate (1-, 3-, 4-, and 6-month 
doses) to determine nadir testosterone levels. Pooled analysis showed 99%, 97%, and 
91% of patients reached nadir testosterone #20, #10, and #5 ng/dL respectively 
(median #3 ng/dL). Across all available categories, $88% of patients reached nadir 
testosterone #5 ng/dL, and ,3% experienced a microsurge. Achievement and mainte-
nance of low nadir testosterone levels may improve progression-free survival and time 
to onset of castrate-resistant prostate cancer.
[Rev Urol. 2018;20(2):63–68 doi: 10.3909/riu0798]
© 2018 MedReviews®, LLC
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Prostate cancer (PCa) is the second most com-mon cancer afflicting men in the United States, with approximately 13% of men receiving this 
diagnosis during their lifetime.1 PCa is an androgen-
dependent neoplasm and proliferates in the presence 
of testosterone (T).2 Suppression of T can inhibit the 
growth of cancer and is the underlying concept for 
androgen deprivation therapy (ADT) based on the 
original research conducted by Huggins and Hodges 
in 1941.3 Luteinizing hormone-releasing hormone 
(LHRH) agonists such as leuprolide acetate (LA) are 
the most commonly used drugs for ADT with the 
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included serum LH, bone pain, uri-
nary symptoms, and World Health 
Organization (WHO) performance 
status. Serum T concentrations 
were measured at screening, base-
line, 2, 4, and 8 hours after dosing, 
days 1, 2, 3, and 7, and then every 
week until the next dose, follow-
ing which the sampling schedule 
was repeated until the end of each 
study.
Assessments
Serum T was measured by radio-
immunoassay with an LOQ of 
3 ng/dL; values below this level were 
recorded as #3 ng/dL. Nadir T was 
defined as the lowest value observed 
during treatment. Serum T and 
nadir T concentrations were sum-
marized using descriptive statis-
tics. Microsurges were identified as 
absolute increases in T of .25 ng/dL 
within 4 weeks after administra-
tion of a second dose. The onset of 
T suppression and the proportion 
of time serum T remained below 
50 ng/dL, 20 ng/dL, and 10 ng/dL 
levels were calculated by extrapo-
lating the point at which the T level 
first crossed the target, calculating 
the total time T levels remained 
below the target, and then dividing 
this by the total time after the target 
was first achieved (Figure 1).
objective of reducing T to castrate 
levels.
In the United States, the bio-
chemical and regulatory definition 
of castration is T ,50 ng/dL, based 
on the sensitivity of the assays 
available when ADT was first 
developed 50 years ago.2,4 With the 
advent of improved assays, T now 
can be measured to much lower 
limits of quantification (LOQ) 
of ,3 ng/dL.5 T levels of 20 to 
32 ng/dL during ADT are associ-
ated with a delay in onset of cas-
trate-resistant PCa (CRPC) and 
lower risk of death for patients 
compared with those with higher T 
levels,2,6 suggesting the lowest pos-
sible serum T should be the objec-
tive of ADT. Consequently, in the 
2012 Bethesda consensus published 
by a group of US experts, a 20 ng/dL 
threshold for serum T during ADT 
in patients with advanced PCa was 
recommended, although American 
Urological Association (AUA) and 
National Comprehensive Cancer 
Network (NCCN) guidelines have 
not adopted this recommendation.7 
In 2014, the European Association 
of Urology (EAU) updated its 
guidelines for the treatment of PCa 
to redefine target level of T during 
ADT to ,20 ng/dL.8
Nadir serum T, the lowest value 
during ADT, has been associated 
with delay in disease progres-
sion and improved survival.9,10 
However, although data on nadir 
T levels have been reported with 
some therapies (ie, abiraterone 
acetate with ADT),11-13 no data 
have been published on nadir T 
levels achieved with LHRH agonist 
monotherapy.
To address this gap in knowl-
edge, a secondary evaluation was 
conducted by pooling patients 
from four pivotal trials of LA 
injected subcutaneously (SC) 
(SC-LA; ELIGARD®, leuprolide 
acetate for injectable suspension; 
Tolmar Pharmaceuticals, Inc., 
Fort Collins, CO). The LA formu-
lations are composed of a unique, 
biodegradable, dual polymer-
based, extended-release delivery 
system. SC-LA is available in 1-, 3-, 
4-, and 6-month doses that form 
solid implants upon interaction 
with SC fluid and subsequently 
slowly release LA.14,15 SC-LA 
maintains mean serum LA levels 
between 0.1 and 1.0 ng/mL and 
produces consistent T suppression 
to #20 ng/dL.16,17
Materials and Methods
Study Design
Data were pooled from four pro-
spective, open-label, fixed-dose 
clinical trials in patients with 
advanced PCa.14-17 Briefly, patients 
aged 40 to 86 years with PCa and 
no prior use of ADT received one 
of four formulations of SC-LA: (1) 
7.5 mg every 28 days for 24 weeks 
(1-month formulation; n 5 120); 
(2) 22.5 mg every 84 days for 24 
weeks (3-month formulation; n 5 
117); (3) 30 mg every 112 days for 
32 weeks (4-month formulation; 
n 5 90); and (4) 45 mg every 168 
days for 48 weeks (6-month for-
mulation; n 5 111) in accordance 
with the manufacturer’s instruc-
tions. The primary endpoint was 
serum T and secondary endpoints 
Figure 1. Proportion of time testosterone below suppression target* (illustrative for T #20 ng/dL). 
*Proportion of time below target calculated by dividing the total time below target by the time after target 
first achieved.
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Results
Patient Demographics and 
Baseline Characteristics
There were 120, 117, 90, and 111 
patients in the 1-, 3-, 4-, and 6-month 
trials, respectively. Baseline char-
acteristics and demographics were 
similar between study cohorts and 
mean baseline serum T concentra-
tions ranged from 361 to 386 ng/dL 
(Table 1). 
Onset and Maintenance of 
Testosterone Suppression
In the pooled population, median 
onsets of T #50, #20, and 
#10 ng/dL were 21, 28, and 35 days, 
respectively (Figure 2A). These 
durations were the same in each 
trial, except for the 1-month for-
mulation where the median onset 
of T #10 ng/dL was 7 days earlier 
at 28 days. The mean proportions 
of time T suppression was main-
tained below each target were 100% 
for T  #50 ng/dL, 94% to 99% for 
T #20 ng/dL, and 66% to 85% for 
T #10 ng/dL (Figure 2B).
Nadir Testosterone
Pooled analysis showed 99%, 97%, 
and 91% of patients reached nadir 
T #20 ng/dL, #10 ng/dL, and 
#5 ng/dL, respectively, with 80% 
achieving a nadir T below the 
LOQ of 3 ng/dL (Figure 3). When 
comparing each formulation, 93%, 
88%, 90%, and 93% of patients who 
received the 1-, 3-, 4-, and 6-month 
doses, respectively, reached a nadir 
T #5 ng/dL.
Testosterone Microsurges
Microsurge in T occurred in 
0.9% to 3.4% (pooled 1.9%) of 
patients across the four studies 
after the second dose (Table 2). 
Of the eight patients who experi-
enced microsurge, six maintained 
T below 50 ng/dL and two patients 
exceeded it. 
Patient Demographics and Baseline Characteristics
TABLE 1
SC-LA Formulated With a Biodegradable, Dual Polymer-based,  
Extended-release Delivery System Dose Groups
1 Month, 7.5 mg 
(n5120)
3 Month, 22.5 mg 
(n5117)
4 Month, 30 mg 
(n590)
6 Month, 45 mg 
(n5111)
Mean age (range) 72.8 (52-85) 73.1 (46-85) 73.5 (53-84) 73.2 (50-86)
Age, years, n (%)
   40-49 0 1 (0.9) 0 0
   50-59 8 (6.7) 6 (5.1) 6 (6.7) 6 (5.4)
   60-69 28 (23.3) 27 (23.1) 20 (22.2) 25 (22.5)
   70-79 60 (50.0) 52 (44.4) 42 (46.7) 55 (49.6)
   80-89 24 (20.0) 31 (26.5) 22 (24.4) 25 (22.5)
Height, in, mean (range) 69.0 (62-75) 68.2 (55-74) 69.0 (60-78) 68.9 (62-76)
Weight, lbs, mean (range) 185.3 (126-287) 186.1 (130-296) 196.5 (133-313) 190.1 (109-321)
Race, n (%)
   White 92 (76.7) 93 (79.5) 71 (78.9) 84 (75.7)
   Black 15 (12.5) 13 (11.1) 10 (11.1) 19 (17.1)
   Hispanic 13 (10.8) 7 (6.0) 8 (8.9) 6 (5.4)
   Asian 0 3 (2.6) 0 1 (0.9)
   Other 0 1 (0.9) 1 (1.1) 1 (0.9)
SC-LA, subcutaneously administered leuprolide acetate.
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Safety
The safety profiles in the pivotal tri-
als have been previously described 
and, as expected, were consistent 
with known effects of LHRH ago-
nist therapy.14–17
Discussion 
Treatment of advanced PCa 
patients with SC-LA resulted 
in reliable T suppression to 
#50 ng/dL by 3 weeks, #20 ng/dL 
Figure 2. (A) Median time to testosterone #10, #20, or #50 ng/dL. (B) Proportion of time testosterone levels 
maintained #10, #20, or #50 ng/dL.
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by 4 weeks, and #10 ng/dL by 
5 weeks. Nadir T levels were below 
the LOQ of 3 ng/dL in 80% and 
#5 ng/dL in 91% of the pooled 
patient population. SC-LA main-
tained consistently low T levels, 
with 100%, 94% to 99%, and 66% 
to 85% of the treatment dura-
tions having T levels below 50, 20, 
and 10 ng/dL, respectively, across 
the four formulations. The inci-
dence of microsurge was 1.9%, 
which is lower than reported for 
intramuscular-LA (4%) in a phase 
3 study.18,19 SC-LA produced pro-
found T suppression to levels 
below historic targets and those 
achieved by surgical castration. 
This T suppression profile may 
extend time to disease progres-
sion and improve patient sur-
vival.9 In some patients, SC-LA 
suppresses T to the very low levels 
reported with the new androgen 
pathway inhibitor drugs for treat-
ment of advanced PCa, such as 
abiraterone acetate (alone or com-
bined with ADT).20,21 Abiraterone 
(a CYP17A1 inhibitor) with ADT 
suppresses T levels to near zero.22 
Enzalutamide and apalutamide, 
also with ADT, impact the andro-
gen signaling pathway by blocking 
the activity of androgens at the AR 
within the cells.23 With the recent 
approvals of abiraterone in meta-
static castrate-sensitive PCa and 
apalutamide in non-metastatic 
CRPC, androgen pathway inhibi-
tors now have indications across a 
wider spectrum of disease, drive 
overall T signaling to near zero, 
and improve survival and other 
endpoints.11,12,22,23 The publica-
tions of studies for these drugs 
do not disclose the magnitude of 
T reductions achieved in patients 
who were randomized to the con-
trol arms that received ADT alone. 
These data would be informative 
and might identify differences in 
T suppression between various 
forms of ADT and their impact on 
clinical endpoints.
Achieving very low nadir T levels 
during the first year of ADT may 
be prognostic for improved cancer-
specific survival.9 It would be infor-
mative to understand how effective 
ADT drugs are in achieving these 
very low levels by consistently mea-
suring T throughout treatment. 
The results of our analyses confirm 
the efficacy of SC-LA in achieving 
and maintaining T levels below 
20 ng/dL, and reaching nadir T 
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for initiating ADT based on the 
available data on T suppression. 
Future studies should assess if 
there are clinical benefits of 
achieving very low nadir T levels 
and compare T suppression levels 
between various drugs and formu-
lations. 
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